CN116003391A - 邻羟基苯基苯酞吡唑酮类化合物及其制备方法和用途 - Google Patents
邻羟基苯基苯酞吡唑酮类化合物及其制备方法和用途 Download PDFInfo
- Publication number
- CN116003391A CN116003391A CN202310109767.7A CN202310109767A CN116003391A CN 116003391 A CN116003391 A CN 116003391A CN 202310109767 A CN202310109767 A CN 202310109767A CN 116003391 A CN116003391 A CN 116003391A
- Authority
- CN
- China
- Prior art keywords
- compound
- hydroxyphenylphthalazinone
- disease
- dementia
- benzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 150000001875 compounds Chemical class 0.000 title claims description 50
- -1 o-hydroxyphenylphthalazinone compound Chemical class 0.000 claims abstract description 55
- 239000003814 drug Substances 0.000 claims abstract description 21
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
- 201000004810 Vascular dementia Diseases 0.000 claims abstract description 8
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 7
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims abstract description 7
- 208000023105 Huntington disease Diseases 0.000 claims abstract description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 208000004296 neuralgia Diseases 0.000 claims abstract description 5
- 208000021722 neuropathic pain Diseases 0.000 claims abstract description 5
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims abstract description 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims abstract description 4
- 201000002832 Lewy body dementia Diseases 0.000 claims abstract description 4
- 208000028389 Nerve injury Diseases 0.000 claims abstract description 4
- 208000024777 Prion disease Diseases 0.000 claims abstract description 4
- 230000008764 nerve damage Effects 0.000 claims abstract description 4
- 238000006243 chemical reaction Methods 0.000 claims description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 5
- 230000000926 neurological effect Effects 0.000 claims description 5
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- 150000002191 fatty alcohols Chemical class 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 206010012289 Dementia Diseases 0.000 claims description 3
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims description 3
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims description 3
- 125000002757 morpholinyl group Chemical group 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 125000003386 piperidinyl group Chemical group 0.000 claims description 3
- 239000007858 starting material Substances 0.000 claims description 3
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 claims description 3
- 239000008096 xylene Substances 0.000 claims description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 13
- 201000010099 disease Diseases 0.000 abstract description 10
- 230000002490 cerebral effect Effects 0.000 abstract description 6
- 206010065040 AIDS dementia complex Diseases 0.000 abstract description 4
- 206010008190 Cerebrovascular accident Diseases 0.000 abstract description 4
- 208000006011 Stroke Diseases 0.000 abstract description 4
- 230000002008 hemorrhagic effect Effects 0.000 abstract description 3
- 230000000302 ischemic effect Effects 0.000 abstract description 3
- 208000014674 injury Diseases 0.000 abstract description 2
- 210000000653 nervous system Anatomy 0.000 abstract description 2
- 230000008733 trauma Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 24
- 230000005764 inhibitory process Effects 0.000 description 17
- 102000010909 Monoamine Oxidase Human genes 0.000 description 15
- 108010062431 Monoamine oxidase Proteins 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 210000004556 brain Anatomy 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 10
- 230000003078 antioxidant effect Effects 0.000 description 9
- 229910021645 metal ion Inorganic materials 0.000 description 8
- 208000015122 neurodegenerative disease Diseases 0.000 description 8
- 230000036542 oxidative stress Effects 0.000 description 7
- 230000008506 pathogenesis Effects 0.000 description 7
- IQHKDZXWJGAZBZ-UHFFFAOYSA-N 4-(2-hydroxyphenyl)-2H-phthalazin-1-one Chemical class Oc1ccccc1-c1n[nH]c(=O)c2ccccc12 IQHKDZXWJGAZBZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 239000003642 reactive oxygen metabolite Substances 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 229960003638 dopamine Drugs 0.000 description 5
- 230000004770 neurodegeneration Effects 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 238000010668 complexation reaction Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 3
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 3
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 210000004623 platelet-rich plasma Anatomy 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- LXEKPEMOWBOYRF-QDBORUFSSA-N AAPH Chemical compound Cl.Cl.NC(=N)C(C)(C)\N=N\C(C)(C)C(N)=N LXEKPEMOWBOYRF-QDBORUFSSA-N 0.000 description 2
- 102100033639 Acetylcholinesterase Human genes 0.000 description 2
- 108010022752 Acetylcholinesterase Proteins 0.000 description 2
- HJXMNVQARNZTEE-UHFFFAOYSA-N Butylphthalide Chemical compound C1=CC=C2C(CCCC)OC(=O)C2=C1 HJXMNVQARNZTEE-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 229940022698 acetylcholinesterase Drugs 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000002555 anti-neurodegenerative effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 2
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 2
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 2
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 2
- 230000003959 neuroinflammation Effects 0.000 description 2
- 238000007833 oxidative deamination reaction Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229940117803 phenethylamine Drugs 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000008057 potassium phosphate buffer Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- PKYCWFICOKSIHZ-UHFFFAOYSA-N 1-(3,7-dihydroxyphenoxazin-10-yl)ethanone Chemical compound OC1=CC=C2N(C(=O)C)C3=CC=C(O)C=C3OC2=C1 PKYCWFICOKSIHZ-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 101000768078 Homo sapiens Amine oxidase [flavin-containing] B Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000006833 Multifunctional Enzymes Human genes 0.000 description 1
- 108010047290 Multifunctional Enzymes Proteins 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940051880 analgesics and antipyretics pyrazolones Drugs 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229950005197 butylphthalide Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000002825 dopamine reuptake Effects 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000000001 effect on platelet aggregation Effects 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003257 excitatory amino acid Substances 0.000 description 1
- 230000002461 excitatory amino acid Effects 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000006951 hyperphosphorylation Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000004848 nephelometry Methods 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000002314 neuroinflammatory effect Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 102000013498 tau Proteins Human genes 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一类邻羟基苯基苯酞吡唑酮类化合物(I)、其制备方法、药物组合物和在制备治疗和/或预防神经系统相关疾病药物中的用途,包括但不限于血管性痴呆、阿尔茨海默氏病、额颞叶痴呆、Prion病、路易体痴呆、帕金森氏症、亨廷顿氏症、HIV相关痴呆症、多发性硬化症、肌萎缩侧索硬化症、神经性疼痛、缺血性脑卒中、出血性脑卒中以及脑外伤引起的神经损伤等疾病;
Description
技术领域
本发明属药物化学领域,涉及一类邻羟基苯基苯酞吡唑酮类化合物(I)、其制备方法、药物组合物和在制备治疗和/或预防神经系统相关疾病药物中的用途,包括但不限于血管性痴呆、阿尔茨海默氏病、额颞叶痴呆、Prion病、路易体痴呆、帕金森氏症、亨廷顿氏症、HIV相关痴呆症、多发性硬化症、肌萎缩侧索硬化症、神经性疼痛、缺血性脑卒中、出血性脑卒中以及脑外伤引起的神经损伤等疾病。
背景技术
神经退行性疾病是指由慢性进行性中枢神经组织退行性变性而产生的疾病总称,包括阿尔茨海默氏病(Alzheimer’s disease,AD)、帕金森氏病(Parkinson’s disease,PD)、亨廷顿氏病(Huntington disease,HD)、肌萎缩侧索硬化症(Amyotrophic lateralsclerosis,ALS)和多发性硬化症(Multiple sclerosis,MS)等,其发病机制与氧化应激、神经炎症及相应的损伤密切相关。氧化应激是由活性氧(Reactive oxygen species,ROS)自由基介导的,包括超氧阴离子、过氧化氢和羟基自由基等。在正常生理条件下,ROS生成水平与机体抗氧化能力处于动态平衡状态,当ROS的产生超过细胞抗氧化能力则会发生氧化应激(Oxidative stress),而大脑对氧化应激尤为敏感,从而诱发多种神经系统疾病。另有研究发现,血管性痴呆、HIV相关痴呆病、神经性疼痛、缺血性脑卒中、出血性脑卒中以及脑外伤引起的神经损伤等也与机体的氧化应激和神经炎症密切相关。
血管性痴呆(Vascular Dementia,VD)是由各种类型的脑血管疾病(包括缺血性脑血管病、出血性脑血管疾病、急性和慢性缺氧性脑血管疾病等)所致的智能及认知功能障碍的临床综合征。血管性痴呆由于发病机制复杂,目前尚无能够阻滞疾病发展的药物,临床治疗以改善脑部血液循环、脑代谢以及加强脑部营养为主。
阿尔茨海默症(老年痴呆症,AD)是一种以进行性认知障碍和记忆力损害为主的中枢神经系统退行性疾病,其发病率呈逐年上升趋势,成为仅次于心血管病和癌症的高发性疾病。随着全球人口老龄化进程的加快,其发病率呈明显上升趋势。据估计,目前全球有超过5000万人患痴呆症,其治疗护理费用总额在2018年已超过1万亿美元,到2050年患病人数将会增加到1.52亿。由于AD临床表现为记忆能力、定向能力、思维和判断能力减退,以及日常生活能力降低,甚至出现异常精神行为症状等,使患者护理难度较大,给社会和家庭带来沉重负担。目前批准用于治疗轻/中度AD的药物有乙酰胆碱酯酶(AChE)抑制剂,以及用于重度AD治疗的N-甲基-D-天冬氨酸(NMDA)受体拮抗剂。但临床使用表明,这些药物可通过提高患者体内乙酰胆碱水平或者抑制兴奋性氨基酸的兴奋毒性来缓解AD症状,但不能有效阻止或逆转病程,而且还会引起幻觉、意识混沌、头晕、恶心、肝脏毒性等严重毒副作用,导致长期疗效不甚理想。因此,临床上迫切需要研发兼具AD症状改善和病程改变的新型AD治疗药物。
AD属多种因素引起的疾病,发病机理复杂,其发病机制至今还未完全阐明。但研究表明,患者脑内乙酰胆碱水平的下降、β-淀粉样蛋白的过度生成与沉积、脑血管内的血小板聚集、金属离子代谢紊乱、Ca2+平衡失调、tau-蛋白过度磷酸化导致的神经纤维缠结、谷氨酸受体活性过高、氧化应激产生大量活性氧(ROS)和自由基以及神经炎症反应等多种因素在AD的发病过程中扮演重要角色。针对上述发病因素,研究人员采用传统“一药一靶”药物设计策略,发现了大量对某一靶点具有高活性和高选择性的药物,如:胆碱酯酶抑制剂和N-甲基-D-天冬氨酸受体拮抗剂等。但这些药物存在作用靶点单一、临床使用毒副作用较多、对AD患者的长期疗效欠佳等问题。
目前,人体内已经鉴定并表征了两种单胺氧化酶(Monoamine oxidases),包括MAO-A和MAO-B两种亚型,它们主要负责5-羟色胺、多巴胺、去甲肾上腺素和苯乙胺等生物胺和单胺类神经递质的氧化脱氨,以调节其在大脑和周围组织中的浓度和代谢。MAO-B主要分布于神经胶质类细胞的线粒体外膜中,并以黄素腺嘌呤二核苷酸(FAD)为辅酶因子,是脑内对多巴胺进行氧化脱氨的主要酶类。近年研究发现,MAO-B在AD或PD患者大脑中的表达量异常增加,该酶不仅可破坏胆碱能神经元,促进Aβ斑块和神经纤维缠结的产生,同时使脑内多巴胺含量显著下降;此外,在MAO-B催化脱氨的同时还会产生H2O2,而生成的H2O2可与内源性Cu2+、Fe2+等离子通过芬顿反应(Fenton reaction)产生羟基自由基,而羟基自由基又可损害脂质、蛋白质和核酸,从而使线粒体功能紊乱,最终导致大脑神经元细胞死亡。因此,抑制MAO-B的脱氨作用既可以提高脑内多巴胺的含量,还可以通过减少自由基、活性氧的产生达到抗氧化应激和神经保护的作用;另有研究发现,抑制MAO-B还可提高脑内苯乙胺含量,通过苯乙胺又可刺激多巴胺的释放和抑制多巴胺的重摄取。因此,发现MAO-B的选择性抑制剂对治疗和/或预防神经系统相关疾病具有重要意义。
近年来,随着对神经退行性疾病致病机理的不断阐明,发现神经退行性疾病的发生和发展具有多机制、多因素作用的特点,不同机制之间又相互关联相互影响,构成了该类疾病发生和发展过程中复杂的网络调控系统。显然,研发可同时作用于神经退行性疾病病理过程中多个环节的治疗药物是目前的必然选择。基于上述结果,研究人员提出了“多靶点导向药物”策略来研发抗神经退行性疾病药物。所谓“多靶点药物”是指单一化学实体同时作用于疾病网络中的多个靶点,对各靶点的作用可产生协同效应,使总效应大于各单效应之和。多靶点药物与多药联合应用以及复方药物的主要区别在于:可减少服药量、提高治疗效果、避免药物之间的相互作用及由此带来的毒副作用,均一的药代动力学特性,便于使用等。因此,研发具有新型化学结构、新型作用机制,且具有多靶点作用、低毒副作用的抗神经退行性疾病治疗药物是当前的重要方向。
发明内容
本发明目的在于公开一类邻羟基苯基苯酞吡唑酮类化合物(I)。
本发明另一目的在于公开该类邻羟基苯基苯酞吡唑酮类化合物(I)的制备方法。
本发明的又一目的在于公开包含该类邻羟基苯基苯酞吡唑酮类化合物(I)的药物组合物。
本发明再一目的在于公开该类邻羟基苯基苯酞吡唑酮类化合物(I)具有多靶点作用,可用于制备治疗和/或预防神经系统相关疾病药物中的用途,包括但不限于血管性痴呆、阿尔茨海默氏病、额颞叶痴呆、Prion病、路易体痴呆、帕金森氏症、亨廷顿氏症、HIV相关痴呆症、多发性硬化症、肌萎缩侧索硬化症、神经性疼痛、缺血性脑卒中、出血性脑卒中以及脑外伤引起的神经损伤等疾病。
本发明所公开的邻羟基苯基苯酞吡唑酮类化合物(I)的化学结构通式为:
式中:X表示O、S或NH;R1表示H、C1~C12烷基、苄基或取代苄基;R2和R3各自独立地表示H、卤素、C1-4烷基、C1-4烷氧基、CF3、CF3O、R4CONH、CN或NR5R6,这些取代基在邻羟基苯基所在的苯环上任意可能的位置;R4表示C1-4烷基;R5和R6各自独立地表示H、C1-4烷基;NR5R6也表示四氢吡咯基、吗啉基或哌啶基;所述化合物为R构型、S构型、或R和S构型的任意比例混合物;所述“卤素”是指F、Cl、Br或I;所述“取代苄基”是指苯环上被1-4个选自下列基团所取代的苄基:F、Cl、Br、I、C1-4烷基、C1-4烷氧基、二甲氨基或氰基,这些取代基在苄基的苯环上任意可能的位置。
本发明所公开的邻羟基苯基苯酞吡唑酮类化合物(I)可通过以下方法制备得到:以相应的4-羟基苯并吡喃-2-酮类化合物(1)为起始原料,在溶剂中与消旋的或手性的6-肼基-3-取代苯酞类化合物(2)反应,即得相应的邻羟基苯基苯酞吡唑酮类化合物(I),其反应式如下:
式中:X、R1、R2和R3的定义与邻羟基苯基苯酞吡唑酮类化合物(I)的化学结构通式相同。
对于上述合成路线,其具体制备方法描述如下:
反应所用溶剂为:C1-6脂肪醇、C1-6脂肪酸、C1-6脂肪酸与C1-6脂肪醇所形成酯、N,N-二甲基甲酰胺、二甲基亚砜、四氢呋喃、乙二醇二甲醚、1,4-二氧六环、苯、甲苯、二甲苯或氯苯,优选溶剂为:N,N-二甲基甲酰胺、甲苯、二甲苯或氯苯;4-羟基苯并吡喃-2-酮类化合物(1):6-肼基-3-取代苯酞类化合物(2)的摩尔投料比为1.0:1.0~5.0,优选摩尔投料比为1.0:1.0~2.0;反应温度为室温~180℃,优选反应温度为80~140℃;反应时间为1~72小时,优选反应时间为4~30小时。
本发明的起始原料——4-羟基苯并吡喃-2-酮类化合物(1)和6-肼基-3-取代苯酞类化合物(2)可用本领域常见的技术制得,包括但不局限于以下文献中所公开的方法:1、K.A.Nolan,et al.J.Med.Chem.2009,52,7142-7156;2、X.Qiang,etal.Bioorg.Med.Chem.Lett.2017,27,718-722。
本发明所公开的药物组合物包括治疗有效量的一种或多种邻羟基苯基苯酞吡唑酮类化合物(I),该药物组合物可进一步含有一种或多种药学上可接受的载体或赋形剂。所述“治疗有效量”是指引起研究者或医生所针对的组织、系统或动物的生物或医药反应的药物或药剂的量;所述“组合物”是指通过将一种以上物质或组份混和而成的产品;所述“药学上可接受的载体”是指药学上可接受的物质、组合物或载体,如:液体或固体填充剂、稀释剂、赋形剂、溶剂或包囊物质,它们携带或转运某种化学物质。本发明所提供的药物组合物其理想的比例是,邻羟基苯基苯酞吡唑酮类化合物(I)作为活性成分占总重量比2%~99.5%。
本发明所公开的邻羟基苯基苯酞吡唑酮类化合物(I)进行了如下的生物活性筛选:
(1)邻羟基苯基苯酞吡唑酮类化合物(I)对单胺氧化酶B的抑制活性
用100mM的pH 7.4磷酸钾缓冲液将重组人MAO-B配成75μg/mL样品液。向黑色96孔板中加入待测化合物溶液20μL,单胺氧化酶80μL,混匀,37℃于避光处孵育15min,加入200μM Amplex Red试剂,2U/mL辣根过氧化物酶,2mM苯甲胺引发反应,37℃孵育20min,在多功能酶标仪上,以固定激发波长545nm,测590nm处荧光发射强度,以磷酸钾缓冲液代替MAO-B为空白;化合物抑制单胺氧化酶的抑制率计算公式为:100-(IFi)/(IFc)*100,式中,IFi和IFc分别为存在抑制剂和无抑制剂下的荧光强度与空白荧光强度的差。每个化合物每次测定3个复孔,每组实验独立重复三次。选择化合物的五至六个浓度,测定其酶抑制率,并以该化合物摩尔浓度的负对数与酶的抑制率线性回归,求得50%抑制率时的摩尔浓度即为该化合物的IC50。测定结果表明,本发明实施例中所公开的邻羟基苯基苯酞吡唑酮类化合物(I)对MAO-B均具有显著抑制作用,其IC50为0.12μM~18.5μM(例如:实施例化合物1-1-1为0.22μM,化合物1-1-2为0.9μM,化合物1-1-4为0.56μM,化合物1-3-13为3.88μM,化合物1-4-1为3.79μM,化合物1-5-7为0.41μM);进一步构效关系研究发现,将邻羟基苯基苯酞吡唑酮类化合物(I)分子中邻羟基苯基所在苯环上的“OH”用“H”替换,所得相应化合物的MAO-B抑制活性均大幅降低,IC50值均大于30μM。
(2)邻羟基苯基苯酞吡唑酮类化合物(I)的抗血小板聚集活性
取雄性家兔3只,用利多卡因局部麻醉,手术分离颈总动脉取血,采取3.8%枸橼酸钠1:9抗凝,以500r/min离心10分钟,制备富血小板血浆(PRP),剩余部分再以3000r/min离心,制备贫血小板血浆(PPP),按比浊法进行血小板聚集实验。测定管中加入240μL的PRP和30μL不同浓度受试药物,温孵5分钟,分别以30μL二磷酸腺苷(ADP)(终浓度为10μmol/L)为诱导剂,观察记录5分钟内最大聚集率;用生理盐水(NS)作对照,计算各受试化合物的抑制率(%)。测定结果表明,本发明实施例中所公开的邻羟基苯基苯酞吡唑酮类化合物(I)对ADP诱导的血小板聚集均有显著抑制作用,其在33.0μM浓度下的抑制率为29.2%~86.8%,在100.0μM浓度下的抑制率均大于50.0%;而阳性对照丁苯酞和阿司匹林在33.0μM浓度下的抑制率分别为9.3%和12.5%。
(3)邻羟基苯基苯酞吡唑酮类化合物(I)的抗氧化活性(ORAC-FL方法)
参照文献(Qiang,X.M.et al.Eur.J Med.Chem.2014,76,314-331)所报道的方法进行测定,即:6-羟基-2,5,7,8-四甲基色烷-2-羧酸(Trolox)用pH7.4的PBS缓冲液配成10-80μmol/L的溶液,荧光素(fluorescein)用pH7.4的PBS缓冲液配成250nmol/L的溶液,2,2’-偶氮二异丁基脒二盐酸盐(AAPH)使用前用pH7.4的PBS缓冲液配成40mmol/L的溶液。向96孔板中加入50-10μmol/L的化合物溶液和荧光素溶液,混匀,37℃孵育15min,加入AAPH溶液,使每孔总体积为200μL,混匀,立即置于Varioskan Flash Multimode Reader(ThermoScientific)仪中,在485nm激发波长和535nm发射波长下连续测定90min。计算出荧光衰减曲线下面积AUC,其中以1-8μmol/L的Trolox作为标准,以不加待测样品为空白,化合物的抗氧化活性结果表达为Trolox的当量,其计算公式为:[(AUC Sample-AUC blank)/(AUCTrolox-AUC blank)]×[(concentration of Trolox/concentration of sample)],每个化合物每次测定3个复孔,每组实验独立重复三次。测定结果表明,本发明实施例中所公开的邻羟基苯基苯酞吡唑酮类化合物(I)的抗氧化活性为Trolox的0.97~3.2倍,说明该类化合物具有较强抗氧化活性。进一步研究发现,将实施例中的邻羟基苯基苯酞吡唑酮类化合物(I)分子中邻羟基苯基所在苯环上的“OH”用“H”替换,所得相应化合物的抗氧化活性均显著降低,其抗氧化活性至少降低1.6-4.5倍,表明邻羟基苯基所在苯环上的“OH”对化合物的抗氧化活性有较重要影响;另外,研究还发现,邻羟基苯基苯酞吡唑酮类化合物(I)的手性中心对其抗氧化活性无影响。
(4)邻羟基苯基苯酞吡唑酮类化合物(I)与金属离子的络合作用
用甲醇溶解CuCl2·2H2O、ZnCl2、FeSO4、AlCl3及待测化合物,配成75μmol/L的溶液,向96孔板中加入100μL待测化合物溶液和100μL金属离子溶液,混匀,室温静置30min,在Varioskan Flash Multimode Reader仪上记录混合物在200-600nm范围内的紫外吸收曲线,并以100μL待测化合物溶液和100μL甲醇混合液为对照,观察金属离子与待测化合物混合液的最大吸收峰的红移现象及最大吸收峰的强度。测定结果表明,本发明实施例中所公开的邻羟基苯基苯酞吡唑酮类化合物(I)对上述金属离子均表现出络合作用;而将其结构中邻羟基苯基所在苯环上的“OH”用“H”替换,所得相应化合物与上述金属离子几乎无络合作用(待测化合物与金属离子混合液的最大吸收峰强度无明显变化,最大吸收峰也无红移现象)。该研究表明,邻羟基苯基所在苯环上的“OH”对化合物的金属离子络合作用有显著影响。
(5)邻羟基苯基苯酞吡唑酮类化合物(I)对神经炎症的抑制活性
(a)化合物和脂多糖(LPS)对BV-2细胞活性的影响
取对数生长期的BV-2细胞配成细胞悬液接种于96孔板,置37℃,5%CO2细胞培养箱内培养24h待细胞贴壁后换为无血清的新鲜培养液90μL,分别加入各浓度待测化合物10μL预孵育30min,每个浓度3个平行孔,同时设空白对照组;然后加或不加LPS,置37℃,5%CO2细胞培养箱内继续培养24h,加入MTT溶液,37℃孵育4h,弃去上清液,每孔加入200μL的DMSO溶液,轻微振荡10min后,用酶标仪在490nm处测定OD值,计算各受试样品不同浓度所测得OD值的均值,并按下列公司计算细胞存活率:细胞存活率(%)=给药组OD均值/对照组OD均值×100%。测试结果表明,本发明实施例中所公开的所有邻羟基苯基苯酞吡唑酮类化合物(I)在不超过25μM浓度下均未显示出细胞毒性(抑制率小于<10%)。
(b)邻羟基苯基苯酞吡唑酮类化合物(I)对LPS诱导的BV-2细胞释放NO的影响
取对数生长期的BV-2细胞配成细胞悬液接种于96孔板,置37℃,5%CO2细胞培养箱内培养24h待细胞贴壁后换为无血清的新鲜培养液90μL,分别加入各浓度待测化合物10μL预孵育30min,每个浓度3个平行孔,同时设空白对照组;然后加入LPS(1.0μg/ml)刺激,置37℃,5%CO2细胞培养箱内继续培养24h,取不同处理组细胞培养上清液,加入等体积的Griess试剂I和等体积的Griess试剂II,室温避光反应10min,在540nm处测定吸光度以检测细胞上清液中NO水平(具体操作按照NO检测试剂盒说明书进行)。测试结果表明,本发明实施例中所公开的所有邻羟基苯基苯酞吡唑酮类化合物(I)在0.5μM至25μM浓度范围内均显示出较强的抑制LPS诱导的BV-2细胞NO生成作用(在5.0μM浓度下的抑制率均超过30.0%),并具有明显的量效关系;表明化合物(I)具有显著的抗神经炎症活性。
具体实施方式
通过下面的实施例可对本发明进行进一步的描述,然而,本发明的范围并不限于下述实施例。本领域的专业人员能够理解,在不背离本发明的精神和范围的前提下,可以对本发明进行各种变化和修饰。
实施例1邻羟基苯基苯酞吡唑酮类化合物(I)的制备通法
在反应瓶中加入相应的4-羟基苯并吡喃-2-酮类化合物(1)(2.0mmol)、6-肼基-3-取代苯酞类化合物(2)(3.0mmol)和甲苯(50ml),然后升温回流搅拌反应5.0~12.0小时(反应进程用TLC跟踪);反应结束后减压蒸除溶剂,残余物经硅胶柱层析纯化(洗脱液:二氯甲烷-乙酸乙酯=15:1v/v),即得相应的邻羟基苯基苯酞吡唑酮类化合物(I),收率40.2%-72.5%,其化学结构均经1H-NMR、13C-NMR和ESI-MS确证,所得目标物的纯度经HPLC测定均大于96.0%。采用上述通法制备得到的目标物结构如下:
部分化合物的1H-NMR数据如下:
1HNMR(DMSO-d6):12.57(s,1H),10.62(s,1H),8.22(dd,J=8.0,1.6Hz,1H,),8.18(d,J=1.2Hz,1H),7.82(d,J=8.4Hz,1H),7.76(dd,J=7.6,1.4Hz,1H),7.23(td,J=8.4,1.6Hz,1H),6.95-6.90(m,2H),6.22(s,1H),5.48(s,2H);
1HNMR(DMSO-d6):12.55(s,1H),10.41(s,1H),8.21(dd,J=8.0,1.2Hz,1H),8.15(s,1H),7.81(d,J=8.4 Hz,1H),7.56(s,1H),7.03(d,J=6.8 Hz,1H),6.83(d,J=8.0 Hz,1H),6.20(s,1H),5.70(dd,J=6.8,3.6 Hz,1H),2.28(s,3H),2.11-2.07(m,1H),1.76-1.74(m,1H),1.37-1.22(m,4H),0.88(t,J=6.6 Hz,3H);
1HNMR(DMSO-d6):12.49(s,1H),10.21(s,1H),8.22(dd,J=8.4,1.6 Hz,1H),8.16(s,1H),7.81(d,J=8.4 Hz,1H),7.28(d,J=2.8 Hz,1H),6.89-6.82(m,2H),6.25(s,1H),5.70(dd,J=7.4,3.8Hz,1H),3.76(s,3H),2.12-2.07(m,1H),1.77-1.73(m,1H),1.42-1.28(m,4H),0.88(t,J=7.0 Hz,3H);
1HNMR(DMSO-d6):12.57(s,1H),10.45(s,1H),8.21(dd,J=8.4,1.8 Hz,1H),8.15(d,J=1.6Hz,1H),7.82(d,J=8.4 Hz,1H),7.64(dd,J=10.0,3.2 Hz,1H),7.06(td,J=8.4,3.2 Hz,1H),6.94(dd,J=9.2,5.2 Hz,1H),6.29(s,1H),5.71(dd,J=7.2,3.6 Hz,1H),2.18-1.97(m,1H),1.80-1.71(m,1H),1.39-1.29(m,4H),0.88(t,J=7.0 Hz,3H);
1HNMR(DMSO-d6):12.61(s,1H),10.65(s,1H),8.22(d,J=7.8 Hz,1H),8.16(s,1H),7.82(d,J=7.8 Hz,1H),7.75(d,J=7.2 Hz,1H),7.23(t,J=7.2 Hz,1H),6.95-6.91(m,2H),6.21(s,1H),5.70(t,J=3.6 Hz,1H),2.10-2.00(m,1H),1.75-1.72(m,1H),1.41-1.23(m,8H),0.86(t,J=6.0Hz,3H);
1HNMR(DMSO-d6):12.51(s,1H),10.69(s,1H),8.23(dd,J=8.2,1.4 Hz,1H),8.16(s,1H),7.84(d,J=2.4 Hz,1H),7.81(d,J=8.4 Hz,1H),7.24(dd,J=8.4,2.2 Hz,1H),6.96(d,J=8.4 Hz,1H),6.30(s,1H),5.69(dd,J=7.6,3.6 Hz,1H),2.11-1.97(m,1H),1.78-1.70(m,1H),1.40-1.24(m,10H),0.85(t,J=6.0 Hz,3H)。
Claims (9)
1.一类邻羟基苯基苯酞吡唑酮类化合物,其特征在于该类化合物的化学结构通式如(I)所示:
式中:X表示O、S或NH;R1表示H、C1~C12烷基、苄基或取代苄基;R2和R3各自独立地表示H、卤素、C1-4烷基、C1-4烷氧基、CF3、CF3O、R4CONH、CN或NR5R6,这些取代基在邻羟基苯基所在的苯环上任意可能的位置;R4表示C1-4烷基;R5和R6各自独立地表示H、C1-4烷基;NR5R6也表示四氢吡咯基、吗啉基或哌啶基;所述化合物为R构型、S构型、或R和S构型的任意比例混合物;所述“卤素”是指F、Cl、Br或I;所述“取代苄基”是指苯环上被1-4个选自下列基团所取代的苄基:F、Cl、Br、I、C1-4烷基、C1-4烷氧基、二甲氨基或氰基,这些取代基在苄基的苯环上任意可能的位置。
2.如权利要求1所述的邻羟基苯基苯酞吡唑酮类化合物,其特征在于R1表示H、C1~C7烷基或苄基。
3.如权利要求1所述的邻羟基苯基苯酞吡唑酮类化合物,其特征在于R2和R3各自独立地表示H、F、Cl、Br、甲基、甲氧基、CF3、CF3O、CH3CONH、CN、NH2、N(CH3)2、四氢吡咯基、吗啉基或哌啶基。
5.如权利要求4所述邻羟基苯基苯酞吡唑酮类化合物的制备方法,其特征在于反应所用溶剂为:C1-6脂肪醇、C1-6脂肪酸、C1-6脂肪酸与C1-6脂肪醇所形成酯、N,N-二甲基甲酰胺、二甲基亚砜、四氢呋喃、乙二醇二甲醚、1,4-二氧六环、苯、甲苯、二甲苯或氯苯。
6.如权利要求4所述邻羟基苯基苯酞吡唑酮类化合物的制备方法,其特征在于4-羟基苯并吡喃-2-酮类化合物(1):6-肼基-3-取代苯酞类化合物(2)的摩尔投料比为1.0:1.0~5.0。
7.如权利要求4所述邻羟基苯基苯酞吡唑酮类化合物的制备方法,其特征在于反应温度为室温~180℃;反应时间为1~72小时。
8.一类药物组合物,其特征在于包含如权利要求1-3任一项所述的邻羟基苯基苯酞吡唑酮类化合物以及一种或多种药学上可接受的载体或赋形剂。
9.如权利要求1-3任一项所述的邻羟基苯基苯酞吡唑酮类化合物在制备治疗和/或预防神经系统相关疾病药物中的用途,这类神经系统相关疾病为:血管性痴呆、阿尔茨海默氏病、额颞叶痴呆、Prion病、路易体痴呆、帕金森氏症、亨廷顿氏症、HIV相关痴呆症、多发性硬化症、肌萎缩侧索硬化症、神经性疼痛、缺血性脑卒中、出血性脑卒中以及脑外伤引起的神经损伤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310109767.7A CN116003391A (zh) | 2023-02-14 | 2023-02-14 | 邻羟基苯基苯酞吡唑酮类化合物及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310109767.7A CN116003391A (zh) | 2023-02-14 | 2023-02-14 | 邻羟基苯基苯酞吡唑酮类化合物及其制备方法和用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116003391A true CN116003391A (zh) | 2023-04-25 |
Family
ID=86021569
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310109767.7A Pending CN116003391A (zh) | 2023-02-14 | 2023-02-14 | 邻羟基苯基苯酞吡唑酮类化合物及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116003391A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6541504B1 (en) * | 2002-04-03 | 2003-04-01 | Allergan Sales, Llc | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors |
CN108069942A (zh) * | 2016-11-10 | 2018-05-25 | 四川大学 | 苯酞吡唑酮类偶联物、其制备方法和用途 |
CN114478450A (zh) * | 2022-01-10 | 2022-05-13 | 四川大学 | 苄氧基苯酞类化合物、其制备方法和用途 |
CN115974854A (zh) * | 2023-02-14 | 2023-04-18 | 四川大学 | 苯酚基烯基苯酞吡唑酮类化合物及其制备方法和用途 |
WO2024054832A1 (en) * | 2022-09-09 | 2024-03-14 | Innovo Therapeutics, Inc. | CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS |
-
2023
- 2023-02-14 CN CN202310109767.7A patent/CN116003391A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6541504B1 (en) * | 2002-04-03 | 2003-04-01 | Allergan Sales, Llc | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors |
CN108069942A (zh) * | 2016-11-10 | 2018-05-25 | 四川大学 | 苯酞吡唑酮类偶联物、其制备方法和用途 |
CN114478450A (zh) * | 2022-01-10 | 2022-05-13 | 四川大学 | 苄氧基苯酞类化合物、其制备方法和用途 |
WO2024054832A1 (en) * | 2022-09-09 | 2024-03-14 | Innovo Therapeutics, Inc. | CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS |
CN115974854A (zh) * | 2023-02-14 | 2023-04-18 | 四川大学 | 苯酚基烯基苯酞吡唑酮类化合物及其制备方法和用途 |
Non-Patent Citations (6)
Title |
---|
SHIQIN CONG,等: "Discovery of novel 5-(2-hydroxyphenyl)-2-phthalide-3(3H)-pyrazolones as balanced multifunctional agents against Alzheimer\'s disease", EUR J MED CHEM ., vol. 250, 15 March 2023 (2023-03-15) * |
TSUNEYUKI KOBAYASHI ,等: "Consecutive Aryne Generation Strategy for the Synthesis of 1, 3-Diarylpyrazoles", J ORG CHEM ., vol. 85, no. 06, 20 March 2020 (2020-03-20), pages 4448 - 4462 * |
叶婵媛: "苯酞与5-芳基吡唑-3-酮杂合物的设计、合成及抗阿尔茨海默病活性研究", 万方学位论文, 1 March 2024 (2024-03-01) * |
孙玉善;刘华骥;淑华;滕有为;: "芳代烷基肼类的化学 Ⅵ.1-芳代烷基-3, 4-环四次甲基吡唑酮-5", 化学学报, no. 06, 30 June 1963 (1963-06-30), pages 40 - 43 * |
张迁: "3-丁基-1(3H)-异苯并呋喃酮衍生物的合成及生物活性研究", 中国优秀硕士学位论文全文数据库 电子期刊 工程科技I辑, no. 07, 15 July 2015 (2015-07-15), pages 016 - 442 * |
朱远群;谭双全;: "丁苯酞联合依达拉奉治疗进展性脑梗死36例临床观察", 中国实用神经疾病杂志, no. 22, 25 November 2010 (2010-11-25), pages 14 - 16 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20170008320A (ko) | 니코틴아미드 리보시드 유사체 및 그의 제약 조성물 및 용도 | |
JP2019108333A (ja) | 置換キノキサリン誘導体およびmGluR4の正のアロステリックモジュレーターとしてのそれらの使用 | |
RU2008148325A (ru) | Полиморфные формы(2s)-(4е)-n-метил-5-(3-изопропоксипиридин)ил) 4-пентен-2амина для лечения расстройств центральной нервной системы | |
JP5913651B2 (ja) | 疼痛および他の疾患の処置のための化合物および方法 | |
WO2015200619A1 (en) | Inhibitors of histone deacetylase | |
CN112010827A (zh) | 一类苄胺基苯酞类化合物、其制备方法和用途 | |
CN115974854B (zh) | 苯酚基烯基苯酞吡唑酮类化合物及其制备方法和用途 | |
CN114478450A (zh) | 苄氧基苯酞类化合物、其制备方法和用途 | |
CN111170884B (zh) | 一类水杨酰胺类化合物、其制备方法和用途 | |
CN110746396B (zh) | 含硒异唑胺类化合物及其制备方法和用途 | |
CN109824637B (zh) | 一种茚酮查尔酮氨基甲酸酯类化合物及其制备方法和用途 | |
CN109734614B (zh) | 3-羟基查尔酮曼尼希碱类化合物、其制备方法和用途 | |
CN109265362B (zh) | 一类2,5-二羟基对苯二甲酰胺类化合物、其制备方法和用途 | |
CN114478451B (zh) | 6-(羟基苄氧基)苯酞曼尼希碱类化合物、其制备方法和用途 | |
KR20140105598A (ko) | [1,2,4]트리아졸로피리딘 및 포스포디에스테라제 억제제로서의 이의 용도 | |
CN108069942A (zh) | 苯酞吡唑酮类偶联物、其制备方法和用途 | |
CN108727352B (zh) | 一类哌啶烷氨甲酰基苯酞类化合物、其制备方法和用途 | |
JP6532880B2 (ja) | Pde1阻害剤としてのヘキサヒドロフロピロール | |
CN116003391A (zh) | 邻羟基苯基苯酞吡唑酮类化合物及其制备方法和用途 | |
CN113105409B (zh) | 2-(羟基苄基)苯并[d]异噻唑酮类化合物、其制备方法和用途 | |
US10494360B2 (en) | Inhibitors of indoleamine 2,3-dioxygenase | |
CN109912443B (zh) | 一类苄胺基氟比洛芬类化合物、其制备方法和用途 | |
CN109912448B (zh) | 一类苄胺基氟比洛芬酰胺类化合物、其制备方法和用途 | |
CN114805263B (zh) | 3-(羟基苄基)苯酞类化合物、其制备方法和用途 | |
CN117143027A (zh) | 3-苄氧基-6-羟苯基哒嗪类化合物及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |